REFERENCES
- Kim AY, Chung RT. Coinfection With HIV-1 and HCV —a one-two punch. Gastroenterology 2009; 137: 795–814.
- Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sat-ten GA et al. Declining morbidity and mortality among patients with ad-vanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. Engl J Med 1998; 338 (13): 853–860.
- Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP et al. Highly active antiretroviral therapy decreases mortality and mor-bidity in patients with advanced HIV disease. J Ann Intern Med 2001; 135 (1): 17–26.
- Tsou LT, Deutschmann EG, Gullen EA, Telpoukhovskaia M, Cheng YC, Hamilton AD. Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold. Bioorg Med Chem Lett 2010; 20 (7): 2137–2139.
- Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 2010; 53: 521–538.
- Tramontano E. The exploding field of the HCV polymerase non-nu-cleoside inhibitors: summary of a first generation compounds. Mini Rev Med Chem 2008; 8 (12): 1298–1231.
- Tramontano E, Di Santo R. HIV-1 RT-associated RNase H function in-hibitors: recent advances in drug development. Curr Med Chem 2010; 17: 2837-2853.
- Priebe W. Anthracycline Antibiotics: New analogues, Method of Delivery, and Mechanisms of Action (ACS Symposium) ed. Waldemar Priebe 1995.
- Arcamone F M. From the pigments of the actinomycetes to third gen-eration antitumor anthracyclines. Biochimie 1998; 80 (3): 201–206.
- Smith A L, Nicolaou K C. The enedyne antibiotics. J Med Chem 1996; 39 (11): 2103–2117.
- Faulds D, Balfour J A, Chrisp P, Langtry HD. Mitoxantrone. A re-view of its pharmacodynamic and pharmacokinetic properties, and thera-peutic potential in the chemotherapy of cancer. Drugs 1991; 41 (3): 400–449.
- De Riccardis FD, Izzo I, Di Filippo M, Sodano G, D'Acquisto F, Car-nuccio R. Synthesis and cytotoxic activity of steroid-anthraquinone hybrids. Tetrahedron 1997; 53 (31): 10871–10882.
- Sokolyuk NT, Romanov VV, Pisulina LP. Naphthacenequinones: syn-thesis and properties. Russian Chem Rev. 1993; 62 (11): 1005–1024.
- Lowen JW. Anthracycline and anthracenedione based anticancer agents: current status and recent developments. Pharmacol Ther 1993; 60 (2): 185–214.
- Kharlamova T, Esposito F, Zinzula L, Floris G, Cheng YC, Deutschmann EG, et al. Inhibition of HIV-1 Ribonuclease H activity by a novel frangula-emodine derivative, 7 brom 6 phenacyl-1,8-dihydroxy-3-methylanthraquinone. Med Chem 2009; 5 (5): 398–410.
- Esposito F, Kharlamova T, Distinto S, Zinzula L, Cheng Y-L, Deutschmann EG, et al. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase (RT)-associated DNA polymerase and Ribonu-clease H (RNase H) activities effective also on the RNase H activity of non-nucleoside resistant RTs. FEBS J. 2011, doi: 10.1111/j.1742-4658. 2011.08057.x.
- Tramontano E, Cheng YC. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem Pharmacol 1992;43 (6): 1371–1376.
- Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 641-(4-Fluorophenyl)methy1-1H-pyrrol 2 ylll 2,4 dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiv Res 2005; 65 (2): 117–124.
- Starnes MC, Cheng YC. Human immunodeficiency virus reverse tran-scriptase-associated RNase H activity. J Biol Chem 1989; 264 (12): 7073–7077.
- Benzaria S, Bardiot D, Bouisset T, Counor C, Rabeson C, Pierra C et al. 2'-C-Methyl branched pyrimidine ribonucleoside analogues: potent in-hibitors of RNA virus replication. Antivir Chem Chemother 2007; 18 (4): 225-242.
- Koyama M, Takahashi K, Chou TC, Darzynkiewicz Z, Kapuscinski J, Kelly TR et al. Intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. J Med Chem 1989; 32 (7): 1594-1599.
- Koyama J, Inoue M, Morita I, Kobayashi N, Osakai T, Nishino H. et al. Correlation between reduction potentials and inhibitory effects on Ep-stein-Barr virus activation by emodin derivatives. Cancer Lett 2006; 241 (2): 263–267.
- Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990; 34 (3): 436–441.